Amycretin, an oral pill, has shown promising results in weight loss compared to existing injectable treatments like Ozempic, Wegovy, and Mounjaro, according to preliminary trial data released on March 7th.
In a three-month placebo-controlled trial, participants taking amycretin lost 13 percent of their body weight, more than double the amount seen with Ozempic and Wegovy specifically. While these findings are encouraging, further research is needed to assess the long-term effectiveness and safety of amycretin compared to other medications, cautioned Daniel Drucker of the University of Toronto.
Ozempic and Wegovy, both containing semaglutide, mimic the gut hormone GLP-1 to reduce appetite and promote fullness. Another injection, Mounjaro, mimics both GLP-1 and GIP and has shown substantial weight loss in early trials. Amycretin, however, mimics GLP-1 and amylin, potentially making it even more potent, especially in the initial three-month period.
While the initial results are promising, direct comparisons between these medications are needed to fully understand their effectiveness and safety profiles. Additionally, the long-term implications of amycretin’s mechanism of action, particularly regarding safety, require further investigation.
Novo Nordisk has reported that the side effects of amycretin are similar to those of Wegovy, including nausea, vomiting, and diarrhea. Moreover, its availability in tablet form could offer a significant advantage for individuals averse to injections, noted Daniel Chancellor of Citeline.